0000939767-18-000054.txt : 20180418 0000939767-18-000054.hdr.sgml : 20180418 20180418201114 ACCESSION NUMBER: 0000939767-18-000054 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180416 FILED AS OF DATE: 20180418 DATE AS OF CHANGE: 20180418 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Garber Alan M CENTRAL INDEX KEY: 0001312907 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30235 FILM NUMBER: 18762307 MAIL ADDRESS: STREET 1: 3355 MILTON COURT CITY: MOUNTAIN VIEW STATE: CA ZIP: 94040 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS, INC. CENTRAL INDEX KEY: 0000939767 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043257395 STATE OF INCORPORATION: DE FISCAL YEAR END: 0102 BUSINESS ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508377000 MAIL ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS INC DATE OF NAME CHANGE: 20000207 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000106 4 1 wf-form4_152409666066391.xml FORM 4 X0306 4 2018-04-16 0 0000939767 EXELIXIS, INC. EXEL 0001312907 Garber Alan M C/O EXELIXIS, INC. 210 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2018-04-16 4 M 0 15000 11.66 A 76329 D Common Stock 2018-04-16 4 S 0 15000 20.25 D 61329 D Option (right to buy) 11.66 2018-04-16 4 M 0 15000 0 D 2011-05-19 2018-05-18 Common Stock 15000.0 0 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2017. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.03 to $20.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2011. /s/ Jennifer Drimmer Rokovich, Attorney in Fact 2018-04-18